Israel seeks first excessive pricing penalty
Israel’s Competition Authority plans to fine a pharmaceutical company €2.3 million for charging excessive prices for a life-saving genetic disorder medication, which would mark the first time the enforcer has issued sanctions for such an infringement.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10